A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Key Inclusion Criteria:

1. Histologically proven aggressive B-NHL, as described in the protocol. Availabilityof tumor tissue for submission to central laboratory is required for studyenrollment. Archival tumor tissue for histological assessment prior to enrollment isallowed

2. Have primary refractory or relapse 12 months or less (≤) from initiation offrontline therapy Only patients who received 1 prior line of therapy containing ananti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed forenrollment

3. Have measurable disease with at least one nodal lesion with longer diameter (LDi)greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm,documented by diagnostic imaging (computed tomography [CT] or magnetic resonanceimaging [MRI])

4. Intent to proceed to autologous stem cell transplant (ASCT), as described in theprotocol

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

6. Adequate hematologic and organ function.

Key Exclusion Criteria:

1. Primary central nervous system (CNS) lymphoma or known involvement by non-primaryCNS NHL, as described in the protocol

2. History of or current relevant CNS pathology, as described in the protocol

3. A malignancy other than NHL unless the participant is adequately and definitivelytreated and is cancer free for at least 3 years, with the exception of localizedprostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanomaskin cancer that was definitively treated

4. Any other significant active disease or medical condition that could interfere withthe conduct of the study or put the participant at significant risk, as described inthe protocol

5. Wash-out period from prior anti-lymphoma treatments and infections, as described inthe protocol

6. Allergy/hypersensitivity to study drug, or excipients.

NOTE: Other protocol defined inclusion / exclusion criteria apply